Adrian Dunlop

4.9k total citations · 1 hit paper
167 papers, 2.7k citations indexed

About

Adrian Dunlop is a scholar working on Epidemiology, Public Health, Environmental and Occupational Health and General Health Professions. According to data from OpenAlex, Adrian Dunlop has authored 167 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Epidemiology, 60 papers in Public Health, Environmental and Occupational Health and 40 papers in General Health Professions. Recurrent topics in Adrian Dunlop's work include Substance Abuse Treatment and Outcomes (63 papers), Opioid Use Disorder Treatment (49 papers) and Prenatal Substance Exposure Effects (28 papers). Adrian Dunlop is often cited by papers focused on Substance Abuse Treatment and Outcomes (63 papers), Opioid Use Disorder Treatment (49 papers) and Prenatal Substance Exposure Effects (28 papers). Adrian Dunlop collaborates with scholars based in Australia, United Kingdom and United States. Adrian Dunlop's co-authors include Nicholas Lintzeris, Paul Haber, Carla Treloar, Iain S. McGregor, Jan Copeland, Gonzalo Rivas, Peter Muhleisen, Suzanne Nielsen, Mark Montebello and Jason Grebely and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Adrian Dunlop

154 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic

2020 202 citations Adrian Dunlop, Michelle Hall et al. profile →

Peers

Adrian Dunlop

EPIDE

PHEOH

PHARM

GHP

PPCH

Jens Reimer Germany

Jeanette M. Tetrault United States

Marica Ferri Portugal

Kanna Hayashi Canada

Linda Gowing Australia

Marcus A. Bachhuber United States

Nadia Fairbairn Canada

Uwe Verthein Germany

Stephen E. Lankenau United States

Samantha Colledge‐Frisby Australia

Jens Reimer Germany

Adrian Dunlop

1.5k ×1.1

EPIDE

1.2k ×1.1

PHEOH

269 ×0.4

PHARM

571 ×1.2

GHP

298 ×0.8

PPCH

Citations per year, relative to Adrian Dunlop Adrian Dunlop (= 1×) peers Jens Reimer

Countries citing papers authored by Adrian Dunlop

Since Specialization

Citations

This map shows the geographic impact of Adrian Dunlop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrian Dunlop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrian Dunlop more than expected).

Fields of papers citing papers by Adrian Dunlop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adrian Dunlop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrian Dunlop. The network helps show where Adrian Dunlop may publish in the future.

Co-authorship network of co-authors of Adrian Dunlop

This figure shows the co-authorship network connecting the top 25 collaborators of Adrian Dunlop. A scholar is included among the top collaborators of Adrian Dunlop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adrian Dunlop. Adrian Dunlop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bonevski, Billie, Jane Rich, Dan I. Lubman, et al.. (2025). Nicotine e-cigarettes for smoking cessation following discharge from smoke-free inpatient alcohol and other drug withdrawal services: a pragmatic two-arm, single-blinded, parallel-group, randomised controlled trial. The Lancet Public Health. 10(7). e568–e577.

White, Bethany, et al.. (2025). Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open‐label, non‐randomised trial of long‐acting injectable buprenorphine treatment in Australian custodial settings. Drug and Alcohol Review. 44(2). 640–648. 1 indexed citations

Trigg, Joshua, Jane Rich, Edwina Williams, et al.. (2024). A qualitative study of using nicotine products for smoking cessation after discharge from residential drug and alcohol treatment in Australia. Drug and Alcohol Review. 43(5). 1116–1131. 1 indexed citations

Ezard, Nadine, Krista J. Siefried, Robert Ali, et al.. (2024). Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo‐controlled trial. Addiction. 120(7). 1345–1359. 2 indexed citations

Brown, Amanda, Amanda Baker, Billie Bonevski, et al.. (2023). Tobacco treatment incorporating contingency management, nicotine replacement therapy, and behavioral counseling for pregnant women who use substances: a feasibility trial. Frontiers in Psychiatry. 14. 1207955–1207955. 1 indexed citations

Ross, Joanne, et al.. (2023). Understanding the research capacity of alcohol and other drugs services in New South Wales, Australia. Drug and Alcohol Review. 43(1). 265–277.

Wand, Handan, Rachel Reilly, Rebecca McKetin, et al.. (2023). Investigating associations between methamphetamine use, mental health and risky sexual behaviours amongst Aboriginal and Torres Strait Islander peoples. Mental Health & Prevention. 30. 200267–200267.

Black, Emma, Rachel Deacon, Nadine Ezard, et al.. (2022). Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016–2019. Drug and Alcohol Review. 42(2). 389–400. 2 indexed citations

Mills, Llewellyn, Rachel Deacon, Raimondo Bruno, et al.. (2021). Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questions. Drug and Alcohol Review. 41(1). 106–113. 6 indexed citations

10.

Deacon, Rachel, Jennifer Holmes, Adrian Dunlop, et al.. (2020). Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations. Drug and Alcohol Review. 39(5). 441–446. 15 indexed citations

11.

Mills, Llewellyn, Nicholas Lintzeris, Raimondo Bruno, et al.. (2020). Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. Drug and Alcohol Review. 39(4). 356–364. 8 indexed citations

12.

Gartner, Coral, Billie Bonevski, Tony Blakely, et al.. (2020). CREATE a New Path to a Smoke-free Australia. QUT ePrints (Queensland University of Technology). 1 indexed citations

13.

Guillaumier, Ashleigh, Eliza Skelton, Anthony Shakeshaft, et al.. (2019). Effect of increasing the delivery of smoking cessation care in alcohol and other drug treatment centres: a cluster‐randomized controlled trial. Addiction. 115(7). 1345–1355. 8 indexed citations

14.

Johnson, Natalie, Kypros Kypri, John B. Saunders, et al.. (2018). Effect of electronic screening and brief intervention on hazardous or harmful drinking among adults in the hospital outpatient setting: A randomized, double-blind, controlled trial. Drug and Alcohol Dependence. 191. 78–85. 9 indexed citations

15.

Nielsen, Suzanne, Nicholas Lintzeris, Bridin Murnion, et al.. (2018). Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. Drug and Alcohol Review. 37(7). 887–896. 5 indexed citations

16.

Alavi, Maryam, Julie Bruneau, Michelle Micallef, et al.. (2016). Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. Journal of Addiction Medicine. 11(1). 10–18. 8 indexed citations

17.

Nielsen, Suzanne, Raimondo Bruno, Bridin Murnion, et al.. (2015). Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia. Drug and Alcohol Review. 35(1). 70–75. 9 indexed citations

18.

Johnson, Natalie, Kypros Kypri, Patrick McElduff, et al.. (2014). Prevalence of unhealthy alcohol use in hospital outpatients. Drug and Alcohol Dependence. 144. 270–273. 9 indexed citations

19.

Hayes, Chris, et al.. (2013). Opioid use in chronic non-cancer pain--part 1: known knowns and known unknowns.. PubMed. 42(3). 98–102. 8 indexed citations

20.

Magin, Parker, Janet Dunbabin, Christopher Oldmeadow, et al.. (2012). An Evaluation of the Prescription of Opioids for Chronic Nonmalignant Pain by Australian General Practitioners. Pain Medicine. 14(1). 62–74. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact